Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

78.81 +1.00 (+1.29%)
Streaming Delayed Price Updated: 12:48 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,451,158
Open 77.78
Bid (Size) 78.80 (2)
Ask (Size) 78.82 (4)
Prev. Close 77.81
Today's Range 77.64 - 78.93
52wk Range 57.16 - 89.74
Shares Outstanding 1,253,809,440
Dividend Yield 3.60%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Gilead Sciences' Debt Overview
 
Via Benzinga
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
From Gilead Sciences, Inc.
Via Business Wire

Performance

YTD
-7.71%
-7.71%
1 Month
-6.89%
-6.89%
3 Month
-7.58%
-7.58%
6 Month
+24.11%
+24.11%
1 Year
+31.39%
+31.39%

More News

Read More
A Bull Market Is Coming: Load Up On These 3 Cheap Stocks Today
Via The Motley Fool
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via TheNewswire.com
Exposures Product Safety
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via News Direct
Exposures Product Safety
Gilead Exercises First License Option Under Agreement With Nurix Therapeutics
Via Benzinga
Gilead Sciences Unusual Options Activity
Via Benzinga
Gilead's Flagship CAR T-cell Therapy Shows Improved Overall Survival In Pretreated Lymphoma Patients
Via Benzinga
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via Benzinga
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
Via Benzinga
A Look Into Gilead Sciences' Debt
Via Benzinga
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Analyst Expectations for Gilead Sciences's Future
Via Benzinga
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
From Gilead Sciences, Inc.
Via Business Wire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Why Shares of MacroGenics Jumped Thursday
Via The Motley Fool
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via News Direct
Topics Economy
Exposures Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via TheNewswire.com
Topics Economy
Exposures Supply Chain
2 Healthcare Stocks That Could Help Set You Up for Life
Via The Motley Fool
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via Benzinga
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Via Talk Markets
7 Cash-Rich Companies to Invest in During Economic Uncertainty
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.